Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accurate antibiotic susceptibility testing is essential for successful tuberculosis treatment. Recent studies have highlighted the limitations of minimum inhibitory concentrations (MIC) based phenotypic susceptibility methods in detecting other aspects of antibiotic susceptibilities in bacteria. Duration and peak of antibiotic exposure, at or above the MIC required for killing the bacterial population, has emerged as another important factor for determining the antibiotic susceptibility. This is broadly defined as antibiotic tolerance. Antibiotic tolerance can further facilitate the emergence of antibiotic resistance. Currently there are limited methods to quantify antibiotic tolerance among clinical <i>M. tuberculosis</i> isolates. In this study, we develop a most-probable number (MPN) based minimum duration of killing (MDK) assay to quantify the spectrum of <i>M. tuberculosis</i> rifampicin susceptibility within subpopulations, based on time duration of rifampicin exposure required for killing the bacterial population. MDK<sub>90</sub>-<sub>99</sub> and MDK<sub>99.99</sub> defined as the minimum time duration of antibiotic exposure at or above MIC required for killing 90-99% and 99.99% of the initial (pre-treatment) bacterial population respectively. Results from the rifampicin MDK assay applied to 28 laboratory and clinical <i>M. tuberculosis</i> isolates showed that there is variation in rifampicin susceptibility among isolates. Rifampicin MDK<sub>99</sub> <b><sub>/</sub></b> <sub>99.99</sub> time for isolates varied from less than 2 to 10 days. MDK was correlated with larger sub-populations of <i>M. tuberculosis</i> from clinical isolates that were rifampicin tolerant. Our study demonstrates the utility of MDK assays to measure the variation in antibiotic tolerance among clinical <i>M. tuberculosis</i> isolates and further expands clinically important aspects of antibiotic susceptibility testing.

Original publication

DOI

10.1128/aac.01439-20

Type

Journal

Antimicrobial agents and chemotherapy

Publication Date

30/11/2020

Addresses

Oxford University Clinical Research Unit, HCMC, Vietnam.